-+ 0.00%
-+ 0.00%
-+ 0.00%

SELLAS LIFE SCIENCES ANNOUNCES POSITIVE PIVOTAL PHASE 3 REGAL TRIAL DATA SHOWING IMMUNOTHERAPEUTIC CANCER VACCINE, GALINPEPIMUT-S (GPS), DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Reuters·11/17/2026 12:00:23

Please log in to view news